Sobi publishes its report for the first quarter 2016 - Seite 2

Financial Summary
	Q1	Q1		Full year
Amounts in SEK M	2016	2015	Change	2015
Total revenues1	1,273	865	47%	3,228
Gross profit	944	519	82%	2,007
Gross margin	74%	60%		62%
EBITA	502	172	>100%	433
EBIT (Operating profit/loss)	410	102	>100%	146
Profit/loss for the period	301	75	>100%	68

¹ Q1 2016 revenues include a one time credit of SEK 322 M relating to first commercial sales of Elocta.

Outlook 2016 unchanged
Sobi continues to expect total revenue for the full year to be in the range of SEK 4,800 to 5,000 M. Revenue will include one-time credits for Elocta of SEK 300 to 325 M and for Alprolix of SEK 300 to 325 M, which will not impact cash. Gross margin is expected be in the range of 68 to 70 per cent.

Sobi will continue to invest in the launches of Elocta and Alprolix, and will also take on incremental costs of SEK 250 - 300 M reflecting its 50 per cent share of Biogen's ongoing development costs for the products. Sobi will assume these costs when it becomes marketing authorisation holder for Elocta, which occurred 24 March 2016; and for Alprolix expected in the second half of the year. These incremental costs are  included in this outlook.

Sobi expects EBITA for the full year to be in the range of SEK 1,200 to 1,300 M.

---

Sobi's report for the first quarter 2016 can be found on http://www.sobi.com/Investors--Media/Reports/.

About Sobi(TM)
Sobi(TM) is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.